跳至主要内容
临床试验/NCT05872425
NCT05872425已完成不适用

Efficacy and Safety of Dingkundan Combined With Combination Oral Contraceptives in the Treatment of PCOS: an Open-label, Non-randomized Controlled Clinical Study

Guangdong Women and Children Hospital1 个研究点 分布在 1 个国家目标入组 120 人开始时间: 2023年2月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
120
试验地点
1
主要终点
Serum androgen

研究概览

简要总结

This is a single-center, non-randomized, open-label clinical study to investigate the efficacy and safety of Dingkundan (DKP) combined with compound oral contraceptives (COC) in the treatment of PCOS. This study is mainly to compare the effect of COC plus DKP verse COC on reducing androgen, improving the function of ovarian and the individual metabolism. The secondary objective of our study is to explore the efficacy of DKP on pregnancy in patients with PCOS and its safety.

详细描述

In this study, the decreased level of serum androgen was used as the main outcome index. It was assumed that PCOS patients treated with Dingkundan combined with compound oral contraceptives for 3 menstrual cycles had decreased serum androgen by 0.53nmol/L. It was assumed that the serum androgen decreased by 0.21nmol/L after 3 menstrual cycles of combined oral contraceptives alone. If α = 0.05, the test degree was 80%, and the dropout rate of 20%, considering that the sample size ratio between the experimental group and control group was 1, the sample size of experimental group and control group were 60 cases each, and 120 cases in total. All the samples were recruited from the Department of Gynecology and Women's Health Care of Guangdong Women and Children's Health Hospital.

This study was approved by the Ethics Committee of the hospital, and all participants are required to sign informed consent.

Before the study, researchers should be trained in a unified and standardized manner, including medication methods, observation indicators, judgment and treatment of adverse reactions/events, and reporting of serious adverse events.

The researcher must adequately and accurately record the research process so that the research data can be verified. These records can be divided into two categories: study documents and raw patient data. Study documents include protocols and amendments, sample informed consent forms, researcher resumes and authorization forms, and other required documents and correspondence. Original documents of patients' include patient inpatient/outpatient records, doctor's and nurse's orders, appointment dates, original laboratory reports, ultrasound, signed informed consent forms, patient screening forms, etc.

During the study period, if the subject withdraws the informed consent, or refuses the further follow-up, or loses follow-up, or dies, the sample will be disqualified.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 35 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Women diagnosed with PCOS.
  • Aged from 18 to 35 years old, in the reproductive age.
  • Have not taken any hormone or Chinese medicine in the past 3 months.

排除标准

  • Age < 18 years or > 35 years.
  • Have taken hormones or Chinese medicine in the last 3 months.
  • Have congenital adrenal hyperplasia, Cushing's syndrome, or androgen-secreting tumors.
  • Abnormal function of liver and kidney.
  • Have hrombotic disease, arterial or venous thromboembolism, or major organic disease.

研究组 & 干预措施

Treatment with DingKunDan(GuangYuYuan) combined with compound oral contraceptives

Experimental

This arm is treated with DingKunDan plus compound oral contraceptives: Drospirenone and Ethinylestradiol Tablets (Ⅱ).

干预措施: DingKunDan(GuangYuYuan) (Drug)

Treatment with DingKunDan(GuangYuYuan) combined with compound oral contraceptives

Experimental

This arm is treated with DingKunDan plus compound oral contraceptives: Drospirenone and Ethinylestradiol Tablets (Ⅱ).

干预措施: Drospirenone and Ethinylestradiol Tablets (Ⅱ) (Drug)

Treatment with compound oral contraceptives

Active Comparator

This arm is only treated with compound oral contraceptives: Drospirenone and Ethinylestradiol Tablets (Ⅱ).

干预措施: DingKunDan(GuangYuYuan) (Drug)

结局指标

主要结局

Serum androgen

时间窗: Before inclusion;after one treatment course.

Basic serum androgen is one of the primary outcome measure and is aim to evaluate the efficacy of Dingkundan that as an adjuvant therapy for PCOS.

Free testosterone

时间窗: Before inclusion;after one treatment course.

Free testosterones is one of the primary outcome measureis aim to evaluate the efficacy of Dingkundan that as an adjuvant therapy for PCOS.

Androstenedione

时间窗: Before inclusion;after one treatment course.

Androstenedione is one of the primary outcome measure is aim to evaluate the efficacy of Dingkundan that as an adjuvant therapy for PCOS.

sex hormone-binding globulin(SHBG)

时间窗: Before inclusion;after one treatment course.

SHBG is one of the primary outcome measure is aim to evaluate the efficacy of Dingkundan that as an adjuvant therapy for PCOS.

次要结局

  • Fasting blood-glucose (FBG)(Before inclusion;after one treatment course.)
  • Fasting insulin (FINS)(Before inclusion;after one treatment course.)
  • HOMA-IR(Before inclusion;after one treatment course.)
  • Anti-Müllerian hormone (AMH)(Before inclusion;after one treatment course.)
  • HCY(Before inclusion;after one treatment course.)

研究者

发起方
Guangdong Women and Children Hospital
申办方类型
Other
责任方
Principal Investigator
主要研究者

Li Li

Deputy Director, Institute of Women's and Children's Health

Guangdong Women and Children Hospital

研究点 (1)

Loading locations...

相似试验